IOA-359 / iOnctura - LARVOL DELTA

Preclinical Activity of Novel TGF Beta Receptor I Kinase Inhibitors IOA-359 and IOA-360 for Treatment of Anemia in MDS/AML (ASH 2023) - "Furthermore, in selected samples, addition of Luspatercept led to greater maturation of erythrocytes. Our current results support the preclinical in vitro efficacy of ALK5 inhibitors IOA-359 and IOA-360 alone and in combination with Luspartercept, highlighting their potential for further development and clinical testing in MDS/AML."

Preclinical • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Hematological Disorders • Myelodysplastic Syndrome • CD34 • GYPA • SMAD2 • TFRC • TGFB1 • TGFBR1

Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS. (PubMed, Leuk Lymphoma) - "ALK5 inhibitors abrogated the growth inhibitory effects of TGF-β on healthy hematopoietic stem cells and stimulated hematopoietic differentiation in cell lines and MDS/AML specimens. These data demonstrate preclinical efficacy of two novel ALK5 inhibitors, IOA-359 and IOA-360, in stimulating erythroid differentiation in MDS and AML."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • TGFB1 • TGFBR1

iOnctura to present research on roginolisib and IOA-359 at ASH (PRNewswire) - "iOnctura...announces abstract data to be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, from 9-12 December 2023...'We are excited to present new research for roginolisib and IOA-359 at ASH. These data highlight the progress we are continuing to make in characterising and targeting resistance mechanisms across a variety of malignancies....at ASH we will present data on the role of TGF-b inhibition in myeloproliferative disorders. Building on our ongoing clinical investigation of roginolisib in patients with lymphoma, we will also present evidence of the synergy between Bcl-2 and PI3Kδ inhibition in Chronic Lymphocytic Leukemia (CLL).'"

Preclinical • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Myeloproliferative Neoplasm

iOnctura expands pipeline and receives development grant from Health Holland and KWF (PRNewswire) - "iOnctura...announces it has exercised an exclusive option with Clavius Pharmaceuticals, adding the novel oral TGF-β pathway inhibitor, IOA-359, to its pipeline. The Company also announces it has, in collaboration with the University of Twente (UT), been awarded a grant from Health Holland and KWF (Dutch Cancer Society), reflecting the potential of IOA-359. Under the terms of the licence agreement, iOnctura is solely responsible for the global development and commercialisation of the small molecule inhibitor....Supplementing iOnctura's internal preclinical investigations, the KWF grant led by Dr Ruchi Bansal, Assistant Professor of Medical Cell BioPhysics, will utilise UT's unique model system to provide iOnctura with a valuable preclinical pharmacology package for IOA-359."

Licensing / partnership • Oncology